![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA GRANTS NOVARTIS PRIORITY REVIEW FOR EXJADE
FDA GRANTS NOVARTIS PRIORITY REVIEW FOR EXJADE
The FDA has granted Novartis priority review status for its new drug application for Exjade (deferasirox), a once-daily oral iron chelator for the treatment of chronic iron overload resulting from blood transfusions.
The priority review establishes an action date for Exjade no later than six months after the May 2005 submission date, Novartis said. Exjade is taken once daily after dispersing tablets in a glass of water or orange juice. The current treatment for the condition requires subcutaneous infusion eight to 12 hours a day, five to seven days a week, as long as the patient receives blood transfusions.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct